advertisement
12 July 2010

HPV vaccine for developing world?

Vaccine manufacturers may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers.

Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy.

At a cost of at least $300 (about R3 000) for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil® from Merck and Cervarix® from GlaxoSmithKline, are some of the most expensive ever introduced.
 

In this study, the researchers gathered and analysed all of the HPV vaccine-related patents that have so far been granted in the US and internationally. That IP landscape is complex, with at least 81 US patents granted to date.

The researchers focused their attention on India, where 19 of 86 international patent applications had been filed by the close of 2008.

Focus on India

India is of special interest because it bears nearly 25% of the global cervical cancer burden, and is a main supplier of childhood vaccines to agencies like the World Health Organization. Its growing middle class is also a potentially large market for the sale of HPV vaccines, Chandrasekharan said.
 

 
NEXT ON HEALTH24X

More:

SexNews
advertisement

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Live healthier

Lifestyle »

E-cigarettes: Here are five things to know

E-cigarettes have become hugely popular in the past decade, but a rash of vaping-linked deaths and illnesses in the US is feeding caution about a product that's already banned in some places.

Allergy »

Ditch the itch: Researchers find new drug to fight hives

A new drug works by targeting an immune system antibody called immunoglobulin E, which is responsible for the allergic reaction that causes hives.